Pfizer and BioNTech have announced the dosing of the first participants of its US Phase I/II Covid-19 vaccine study. The pair has four vaccine candidates against the novel coronavirus in the BNT162 development programme; a study of these products are already underway in Germany.

Pfizer chairman and CEO Albert Bourla said: “With our unique and robust clinical study program underway, starting in Europe and now the US we look forward to advancing quickly and collaboratively with our partners at BioNTech and regulatory authorities to bring a safe and efficacious vaccine to the patients who need it most.

“The short, less than four-month timeframe in which we’ve been able to move from pre-clinical studies to human testing is extraordinary and further demonstrates our commitment to dedicating our best-in-class resources, from the lab to manufacturing and beyond, in the battle against Covid-19.”

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData